Cognition Therapeutics Reports Phase 2 Results Showing Zervimesine Slows Progression of Dementia with Lewy Bodies

Reuters01-06

Cognition <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Phase 2 Results Showing Zervimesine Slows Progression of Dementia with Lewy Bodies

Cognition Therapeutics Inc. has announced the publication of Phase 2 clinical results for zervimesine (CT1812) in participants with mild-to-moderate dementia with Lewy bodies $(DLB)$. The data, published in the journal Alzheimer's & Dementia, demonstrated that zervimesine led to improvements in behavioral, functional, cognitive, and movement measures compared to placebo. The Phase 2 SHIMMER study met its primary endpoint of confirming the safety and tolerability of zervimesine, and showed favorable effects on several core clinical features of DLB, including cognitive fluctuations and activities of daily living. Results from the study were first presented in January 2025 at the International Lewy Body Dementia Conference. The U.S. Food and Drug Administration is scheduled to meet with Cognition Therapeutics in the second half of January 2026 to discuss the next clinical studies for zervimesine in DLB.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cognition Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9620333-en) on January 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601892550?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-06 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601892550","market":"fut","top_or_hot":-1,"title":"Cognition Therapeutics Reports Phase 2 Results Showing Zervimesine Slows Progression of Dementia with Lewy Bodies","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cognition <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Phase 2 Results Showing Zervimesine Slows Progression of Dementia with Lewy Bodies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cognition Therapeutics Inc. has announced the publication of Phase 2 clinical results for zervimesine (CT1812) in participants with mild-to-moderate dementia with Lewy bodies <a href=\"https://laohu8.com/S/DLB\">$(DLB)$</a>. The data, published in the journal Alzheimer's &amp; Dementia, demonstrated that zervimesine led to improvements in behavioral, functional, cognitive, and movement measures compared to placebo. The Phase 2 SHIMMER study met its primary endpoint of confirming the safety and tolerability of zervimesine, and showed favorable effects on several core clinical features of DLB, including cognitive fluctuations and activities of daily living. Results from the study were first presented in January 2025 at the International Lewy Body Dementia Conference. The U.S. Food and Drug Administration is scheduled to meet with Cognition Therapeutics in the second half of January 2026 to discuss the next clinical studies for zervimesine in DLB.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cognition Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9620333-en) on January 06, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cognition Therapeutics Reports Phase 2 Results Showing Zervimesine Slows Progression of Dementia with Lewy Bodies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCognition Therapeutics Reports Phase 2 Results Showing Zervimesine Slows Progression of Dementia with Lewy Bodies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-06 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cognition <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Phase 2 Results Showing Zervimesine Slows Progression of Dementia with Lewy Bodies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cognition Therapeutics Inc. has announced the publication of Phase 2 clinical results for zervimesine (CT1812) in participants with mild-to-moderate dementia with Lewy bodies <a href=\"https://laohu8.com/S/DLB\">$(DLB)$</a>. The data, published in the journal Alzheimer's &amp; Dementia, demonstrated that zervimesine led to improvements in behavioral, functional, cognitive, and movement measures compared to placebo. The Phase 2 SHIMMER study met its primary endpoint of confirming the safety and tolerability of zervimesine, and showed favorable effects on several core clinical features of DLB, including cognitive fluctuations and activities of daily living. Results from the study were first presented in January 2025 at the International Lewy Body Dementia Conference. The U.S. Food and Drug Administration is scheduled to meet with Cognition Therapeutics in the second half of January 2026 to discuss the next clinical studies for zervimesine in DLB.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cognition Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9620333-en) on January 06, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014021.USD","symbol_name":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL8vMVlh:1","article_id":"2601892550","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601892550","pubTimestamp":1767702617,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cognition Therapeutics Inc. has announced the publication of Phase 2 clinical results for zervimesine  in participants with mild-to-moderate dementia with Lewy bodies . The data, published in the journal Alzheimer's & Dementia, demonstrated that zervimesine led to improvements in behavioral, functional, cognitive, and movement measures compared to placebo. The Phase 2 SHIMMER study met its primary endpoint of confirming the safety and tolerability of zervimesine, and showed favorable effects on several core clinical features of DLB, including cognitive fluctuations and activities of daily living. Results from the study were first presented in January 2025 at the International Lewy Body Dementia Conference. The U.S. Food and Drug Administration is scheduled to meet with Cognition Therapeutics in the second half of January 2026 to discuss the next clinical studies for zervimesine in DLB.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligen","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","BK4588":"碎股","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4112":"金融交易所和数据","CGTX":"Cognition Therapeutics, Inc","BK4585":"ETF&股票定投概念","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","BK4007":"制药"},"translate_title":"Cognition Therapeutics报告2期结果显示Zervimesine可减缓路易体痴呆的进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"CGTX":0.9},"content_text":"Cognition Therapeutics Reports Phase 2 Results Showing Zervimesine Slows Progression of Dementia with Lewy Bodies\n    \n\n        Cognition Therapeutics Inc. has announced the publication of Phase 2 clinical results for zervimesine (CT1812) in participants with mild-to-moderate dementia with Lewy bodies $(DLB)$. The data, published in the journal Alzheimer's & Dementia, demonstrated that zervimesine led to improvements in behavioral, functional, cognitive, and movement measures compared to placebo. The Phase 2 SHIMMER study met its primary endpoint of confirming the safety and tolerability of zervimesine, and showed favorable effects on several core clinical features of DLB, including cognitive fluctuations and activities of daily living. Results from the study were first presented in January 2025 at the International Lewy Body Dementia Conference. The U.S. Food and Drug Administration is scheduled to meet with Cognition Therapeutics in the second half of January 2026 to discuss the next clinical studies for zervimesine in DLB.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cognition Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9620333-en) on January 06, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601892550","isCrawlerRequest":true}